Leaders in blood banking and transfusion medicine have been the driving force behind the development of the U.S. Biovigilance Network. The success of the network, however, is contingent on involvement from all segments of the community. The greater the participation, the more data will be available and the more powerful they will be. The following are quotes from network advocates, expressing their support for the initial concept as well as the actual systems in place to track and analyze data on transfusion- and blood collection-related adverse events.
Donor Hemovigilance System
“A nationwide biovigilance network is absolutely critical for patient safety, public health and adoption of best practices. That’s why Blood Systems has committed $350,000 in support of the Network, helping ensure the safety of America’s blood and tissue services.”
— J. Daniel Connor, President and CEO, Blood Systems Inc.
“The quality gurus say, ‘If you can't measure it, you can’t improve it.’ The biovigilance network will allow us to see what's happening in transfusion and transplantation, use experts to analyze the situation, and recommend improvements in the system leading to augmented patient safety.”
— James AuBuchon, MD, President and CEO, Puget Sound Blood Center
“The Department of Health and Human Services and the Centers for Disease Control and Prevention initial funding of this project is a powerful endorsement of the network’s value to patients and the public health. This is precisely the kind of leadership that will ultimately enhance patient safety and reduce costs — we hope the private sector will continue to fully step up to the plate.”
— Karen Shoos Lipton, CEO, AABB
“The purpose of this group is … to get into the mindset of … the Hemovigilance Module and establish in our documentation and database assets commonality with the system to facilitate reporting.”
— Chet Andrzejewski, MD, PhD, Medical Director, Baystate Medical Center
“[By enrolling in the CDC’s NHSN Hemovigilance Module], we will be able to use a single document to report information to the NHSN, AABB and possibly the Massachusetts Department of Public Health.”
— Leslie Richardson-Weber, MT(ASCP), Blood Bank Clinical Manager, Beth Israel Deaconess Medical Center
“We were amazed at how quickly we discovered a trend with only a small amount of data. This is exactly what we wanted out of the Hemovigilance Module – to be able to recognize problems right away and eliminate them to make conditions better for patients.”
— Christi Marshall, MT(ASCP)BB, CQA(ASQ), Laboratory Supervisor, Johns Hopkins Hospital
“Many facilities that have enrolled [in CDC’s NHSN Hemovigilance Module] are reporting that they have quickly embraced the Hemovigilance Module and are considering it an invaluable part of their institutions’ quality programs.”
— Matt Kuehnert, MD, Director, Office of Blood, Organ and Other Tissue Safety, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention
Donor Hemovigilance System
"Newly participating blood centers will likely be surprised at how easy some sophisticated analyses are to accomplish with the donor hemovigilance system."
— Peter Tomasulo, MD, FACP, Executive Vice President, Blood Systems Inc.
“The best thing to do is to start today – beginning is easier than some may think. Cold, hard, well-organized data can be nothing but eye-opening.”
— Mary Townsend, MD, Regional Medical Director, Blood Systems Inc.
Return to U.S. Biovigilance Network